Search

Your search keyword '"Monforte, A D’Arminio"' showing total 1,041 results

Search Constraints

Start Over You searched for: Author "Monforte, A D’Arminio" Remove constraint Author: "Monforte, A D’Arminio"
1,041 results on '"Monforte, A D’Arminio"'

Search Results

1. Clinical Outcome and 7-Day Virological Clearance in High-Risk Patients with Mild–Moderate COVID-19 Treated with Molnupiravir, Nirmatrelvir/Ritonavir, or Remdesivir

3. Clinical and laboratory predictors of mpox severity and duration: an Italian multicentre cohort study (mpox-Icona)

5. EuCARE-POSTCOVID Study: a multicentre cohort study on long-term post-COVID-19 manifestations

6. Heavy antiretroviral exposure and exhausted/limited antiretroviral options: predictors and clinical outcomes

8. Trends in mortality in people with HIV from 1999 to 2020: a multi-cohort collaboration

9. FRI-442 Disease progression and persistent alanine aminotransferase elevation in HCV/HIV persons after DAA-related eradication: role of HBV and HDV co-infections

12. What is the impact of SARS-CoV-2 pandemic on antimicrobial stewardship programs (ASPs)? The results of a survey among a regional network of infectious disease centres

13. Long-acting injectable antiretrovirals for HIV treatment in the ICONA cohort: physicians' and nurses' points of view.

14. Dynamics of viral DNA shedding and culture viral DNA positivity in different clinical samples collected during the 2022 mpox outbreak in Lombardy, Italy

15. Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study

16. Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy

18. Do we Still Need Eligibility Criteria to Recommend PrEP? Impact of National Prescribing Requirements on Retention in Care and Sexually Transmitted Infections Acquisition

19. Dynamics of viral DNA shedding and culture viral DNA positivity in different clinical samples collected during the 2022 mpox outbreak in Lombardy, Italy

20. Cost-effectiveness of statins for primary prevention of atherosclerotic cardiovascular disease among people living with HIV in the United States

21. Sustained virological response after treatment with direct antiviral agents in individuals with HIV and hepatitis C co‐infection

22. Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort.

23. Chronic Liver Enzyme Elevation and Use of Contemporary ARVs Among People With HIV.

24. Performance evaluation of a self-administered point of-care test for anal HPV screening in PrEP users: data from a community-based PrEP service.

25. Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study

26. Heavy arv exposure and exhausted/limited arv options: predictors and clinical outcomes

27. Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV

28. Measures of Longitudinal Immune Dysfunction and Risk of AIDS and Non-AIDS Defining Malignancies in Antiretroviral-Treated People With Human Immunodeficiency Virus.

30. SARS-CoV-2 mRNA vaccination and short-term changes in viral load and CD4/CD8 T-cell counts in people living with HIV

31. Female gender is associated with long COVID syndrome: a prospective cohort study

32. CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus–Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC)

33. The Human Immunodeficiency Virus Continuum of Care in European Union Countries in 2013: Data and Challenges

34. Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients With HIV/HCV Coinfection: Results of an Italian Compassionate Use Program

35. HCV elimination in persons living with HIV (PLWH): the NoCo (No-Coinfection) study of the ICONA network

36. Ultrasensitive HBV-RNA quantification by droplet digital PCR is a promising biomarker to optimize the staging of chronic HBV infection and to identify minimal viral activity under prolonged virological suppression

37. Hepatitis delta virus (HDV) infection : frequency and outcome in persons living with HIV (PLWH). Data from the ICONA (Italian cohort of naïve for antiretrovirals) cohort

38. Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial

39. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies

40. Determinants of worse liver-related outcome according to HDV infection among HBsAg positive persons living with HIV: Data from the ICONA cohort.

42. Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D Study

45. Real world efficacy of dolutegravir plus lamivudine in people living with HIV with undetectable viral load after previous failures

46. Contribution of alcohol use in HIV/hepatitis C virus co-infection to all-cause and cause-specific mortality:A collaboration of cohort studies

49. Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study

Catalog

Books, media, physical & digital resources